专利检索 ap:("Novartis AG" OR "Novartis Pharma GmbH") AND inv:"SELLNER, Holger" 第 1 页

1.

发明公开
3,4-SUBSTITUTED PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF HYPERTENSION 有权
标题翻译： 3,4-取代的吡咯烷衍生物对治疗高血压病

公开(公告)号：EP1863477A1

公开(公告)日：2007-12-12

申请号：EP06707621.6

申请日：2006-03-21

申请人： Novartis AG , NOVARTIS-PHARMA GMBH

发明人： SELLNER, Holger , OSTERMANN, Nils , MAIBAUM, Juergen, Klaus , LORTHIOIS, Edwige, Liliane, Jeanne , IRIE, Osamu NOvartis Pharma K.K. , EHRHARDT, Claus

IPC分类号： A61K31/4025 , A61K31/341 , A61K31/351 , A61K31/357 , A61K31/4035 , A61K31/404 , A61K31/416 , A61K31/422 , A61K31/4409 , A61K31/454 , A61K31/4704 , A61K31/506 , A61K31/5355 , A61K31/5377

CPC分类号： C07D207/27 , A61K31/341 , A61K31/351 , A61K31/352 , A61K31/357 , A61K31/4025 , A61K31/4035 , A61K31/404 , A61K31/416 , A61K31/422 , A61K31/423 , A61K31/4409 , A61K31/454 , A61K31/4704 , A61K31/506 , A61K31/5355 , A61K31/5377 , C07D207/09 , C07D207/16 , C07D401/12 , C07D403/12 , C07D405/12 , C07D413/12

摘要： The invention relates to the use of (3,4-di-, 3,3,4-tri, 3,4,4-tri- or 3,3,4,4-tetra-)substituted pyrrolidine compounds for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; compounds that are part of a subclass of these substituted pyrrolidine compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (= disorder) that depends on activity of renin; new compounds that are part of a subclass of these substituted pyrrolidine compounds; pharmaceutical formulations comprising said substituted pyrrolidine compounds, and/or a method of treatment comprising administering said substituted pyrrolidine compounds, a method for the manufacture especially of said new substituted pyrrolidine compounds, as well as novel intermediates, starting materials and/or partial steps for their synthesis. The substituted pyrrolidine compounds are of the formula (I), wherein R1, R2, R3, R4, R5 and T are defined as in the specification.

2.

发明授权
3,4-SUBSTITUTED PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF HYPERTENSION 有权
标题翻译： 3,4-取代的吡咯烷衍生物对治疗高血压病

公开(公告)号：EP1863477B1

公开(公告)日：2010-11-03

申请号：EP06707621.6

申请日：2006-03-21

申请人： Novartis AG , Novartis Pharma GmbH

发明人： SELLNER, Holger , OSTERMANN, Nils , MAIBAUM, Juergen, Klaus , LORTHIOIS, Edwige, Liliane, Jeanne , IRIE, Osamu , EHRHARDT, Claus

IPC分类号： A61K31/4025 , A61K31/341 , A61K31/351 , A61K31/357 , A61K31/4035 , A61K31/404 , A61K31/416 , A61K31/422 , A61K31/4409 , A61K31/454 , A61K31/4704 , A61K31/506 , A61K31/5355 , A61K31/5377 , A61P9/12

CPC分类号： C07D207/27 , A61K31/341 , A61K31/351 , A61K31/352 , A61K31/357 , A61K31/4025 , A61K31/4035 , A61K31/404 , A61K31/416 , A61K31/422 , A61K31/423 , A61K31/4409 , A61K31/454 , A61K31/4704 , A61K31/506 , A61K31/5355 , A61K31/5377 , C07D207/09 , C07D207/16 , C07D401/12 , C07D403/12 , C07D405/12 , C07D413/12

摘要： The invention relates to the use of (3,4-di-, 3,3,4-tri, 3,4,4-tri- or 3,3,4,4-tetra-)substituted pyrrolidine compounds for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on activity of renin; the use of a compound of that class in the treatment of a disease that depends on activity of renin; compounds that are part of a subclass of these substituted pyrrolidine compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (= disorder) that depends on activity of renin; new compounds that are part of a subclass of these substituted pyrrolidine compounds; pharmaceutical formulations comprising said substituted pyrrolidine compounds, and/or a method of treatment comprising administering said substituted pyrrolidine compounds, a method for the manufacture especially of said new substituted pyrrolidine compounds, as well as novel intermediates, starting materials and/or partial steps for their synthesis. The substituted pyrrolidine compounds are of the formula (I), wherein R1, R2, R3, R4, R5 and T are defined as in the specification.

3.

发明公开
4-PHENYLPIPERIDINE DERIVATIVES AS RENIN INHIBITORS 有权
标题翻译：作为肾素抑制剂4-苯基哌啶衍生物

公开(公告)号：EP1689712A1

公开(公告)日：2006-08-16

申请号：EP04798086.7

申请日：2004-11-25

申请人： Novartis AG , NOVARTIS-PHARMA GMBH

发明人： SEDRANI, Richard , MAIBAUM, Jürgen, Klaus , BREITENSTEIN, Werner , SELLNER, Holger , EHRHARDT, Claus , OSTERMANN, Nils

IPC分类号： C07D211/42 , C07D405/04 , C07D401/10 , C07D409/10 , A61K31/4418 , A61K31/443 , A61K31/4436 , A61K31/4439 , A61K31/444

CPC分类号： C07D401/10 , C07D211/42 , C07D405/04 , C07D409/10

摘要： Compounds of the present invention having the formula (I) exhibit inhibitory activity on the natural enzyme renin. Thus, compounds of formula (I) may be employed for the treatment of hypertension, atherosclerosis, unstable coronary syndrome, congestive heart failure, cardiac hypertrophy, cardiac fibrosis, cardiomyopathy postinfarction, unstable coronary syndrome, diastolic dysfunction, chronic kidney disease, hepatic fibrosis, complications resulting from diabetes, such as nephropathy, vasculopathy and neuropathy, diseases of the coronary vessels, restenosis following angioplasty, raised intra-ocular pressure, glaucoma, abnormal vascular growth, hyperaldosteronism, cognitive impairment, alzheimers, dementia, anxiety states and cognitive disorders.

4.

发明授权
4-PHENYLPIPERIDINE DERIVATIVES AS RENIN INHIBITORS 有权
标题翻译： 4- PHENYLPIPERIDINDERIVATE ALS RENININHIBITOREN

公开(公告)号：EP1689712B1

公开(公告)日：2009-08-19

申请号：EP04798086.7

申请日：2004-11-25

申请人： NOVARTIS AG , NOVARTIS-PHARMA GMBH

发明人： SEDRANI, Richard , MAIBAUM, Jürgen, Klaus , BREITENSTEIN, Werner , SELLNER, Holger , EHRHARDT, Claus , OSTERMANN, Nils

IPC分类号： C07D211/42 , C07D405/04 , C07D401/10 , C07D409/10 , A61K31/4418 , A61K31/443 , A61K31/4436 , A61K31/4439 , A61K31/444

CPC分类号： C07D401/10 , C07D211/42 , C07D405/04 , C07D409/10

摘要： Compounds of the present invention having the formula (I) exhibit inhibitory activity on the natural enzyme renin. Thus, compounds of formula (I) may be employed for the treatment of hypertension, atherosclerosis, unstable coronary syndrome, congestive heart failure, cardiac hypertrophy, cardiac fibrosis, cardiomyopathy postinfarction, unstable coronary syndrome, diastolic dysfunction, chronic kidney disease, hepatic fibrosis, complications resulting from diabetes, such as nephropathy, vasculopathy and neuropathy, diseases of the coronary vessels, restenosis following angioplasty, raised intra-ocular pressure, glaucoma, abnormal vascular growth, hyperaldosteronism, cognitive impairment, alzheimers, dementia, anxiety states and cognitive disorders.

5.

发明公开
DELTA-AMINO-GAMMA-HYDROXY-OMEGA-ARYL-ALKANOIC ACID AMIDES AND USE AS RENIN INHIBITORS 审中-公开
标题翻译： DELTA氨基GAMMA羟基OMEGA-ARYLALKYLSÄUREAMIDE与应用，肾素抑制剂

公开(公告)号：EP1692095A1

公开(公告)日：2006-08-23

申请号：EP04819639.8

申请日：2004-11-30

申请人： Novartis AG , Novartis Pharma GmbH

发明人： SELLNER, Holger , GROSS, Gerhard , MAIBAUM, Juergen, Klaus , COTTENS, Sylvain

IPC分类号： C07C237/22 , A61K31/165

CPC分类号： C07C237/22

摘要： The invention relates to novel δ-amino-Ϝ-hydroxy-ω-aryl-alkanoic acid amides of formula (I), or a pharmaceutically acceptable salt thereof.

6.

发明公开
ORGANIC COMPOUNDS 有权
标题翻译：有机化合物

公开(公告)号：EP1689702A1

公开(公告)日：2006-08-16

申请号：EP04819222.3

申请日：2004-11-25

申请人： NOVARTIS-PHARMA GMBH , Novartis AG

发明人： NOVARTIS AG , BAESCHLIN, Daniel, Kaspar , MAIBAUM, Jürgen, Klaus , SELLNER, Holger

IPC分类号： C07C237/20 , C07D295/02 , C07C237/24 , C07C271/24 , C07C323/29 , C07C255/50 , C07D319/18 , C07D313/08 , C07D307/79 , C07D207/09 , C07D333/08 , A61P9/12 , A61K31/165 , A61K31/325 , A61K31/44

CPC分类号： C07C237/20 , C07C237/24 , C07C255/60 , C07C271/22 , C07C271/24 , C07C323/41 , C07C2601/02 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07C2601/18 , C07C2602/08 , C07C2602/42 , C07D207/09 , C07D295/027 , C07D307/79 , C07D313/08 , C07D319/18 , C07D333/08

摘要： Disclosed are δ-amino-Ϝ-hydroxy-ω-aryl-alkanoic acid amide compounds of formula (I) and the salts thereof, having renin-inhibiting properties. Also disclosed are pharmaceutical compositions comprising these compounds and methods of administering them for the treatment of hypertension, atherosclerosis, unstable coronary syndrome, congestive heart failure, cardiac hypertrophy, cardiac fibrosis, cardiomyopathy postinfarction, unstable coronary syndrome, diastolic dysfunction, chronic kidney disease, hepatic fibrosis, complications resulting from diabetes, such as nephropathy, vasculopathy and neuropathy, diseases of the coronary vessels, restenosis following angioplasty, raised intra-ocular pressure, glaucoma, abnormal vascular growth, hyperaldosteronism, cognitive impairment, alzheimers, dementia, anxiety states and cognitive disorders.

摘要翻译： 公开了具有肾素抑制性质的式（I）的δ-氨基-β-羟基-ω-芳基 - 链烷酸酰胺化合物及其盐。还公开了包含这些化合物的药物组合物和施用它们以治疗高血压，动脉粥样硬化，不稳定冠状动脉综合征，充血性心力衰竭，心脏肥大，心脏纤维化，心肌梗塞后梗塞，不稳定冠状动脉综合征，舒张功能障碍，慢性肾病，肝纤维化，由糖尿病引起的并发症如肾病，血管病和神经病，冠状血管疾病，血管成形术后再狭窄，眼内压升高，青光眼，血管生长异常，醛固酮增多症，认知障碍，阿尔茨海默病，痴呆，焦虑状态和认知障碍。

7.

发明公开
PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN 有权
标题翻译：吡咯烷肾素依赖性疾病的活性的治疗

公开(公告)号：EP1836163A2

公开(公告)日：2007-09-26

申请号：EP05825434.3

申请日：2005-12-21

申请人： Novartis AG , Novartis Pharma GmbH

发明人： BREITENSTEIN, Werner , COTTENS, Sylvain , EHRHARDT, Claus , JACOBY, Edgar , LORTHIOIS, Edwige, Liliane, Jeanne , MAIBAUM, Juergen, Klaus , OSTERMANN, Nils , SELLNER, Holger , SIMIC, Oliver

IPC分类号： C07D207/09 , C07D207/14 , C07D401/12 , C07D405/12 , C07D403/12 , C07D409/12 , C07D207/08 , C07D413/12 , C07D417/12 , C07D491/10 , A61K31/40 , A61K31/41 , A61K31/435 , A61K31/54 , A61P9/00

CPC分类号： C07D207/08 , C07D207/09 , C07D207/14 , C07D401/12 , C07D403/12 , C07D405/12 , C07D409/12 , C07D413/12 , C07D417/12 , C07D491/10

摘要： Novel 3-mono-, 3,4-di- and 3,4,4,-tri-substituted pyrrolidine compounds, these compounds for use in the diagnostic and therapeutic treatment of a warm-blooded animal, especially for the treatment of a disease (= disorder) that depends on inappropriate activity of renin; the use of a compound of that class for the preparation of a pharmaceutical formulation for the treatment of a disease that depends on inappropriate activity of renin; the use of a compound of that class in the treatment of a disease that depends on inappropriate activity of renin; pharmaceutical formulations comprising a said substituted pyrrolidine compound, and/or a method of treatment comprising administering a said substituted pyrrolidine compound, a method for the manufacture of said substituted pyrrolidine compounds, and novel intermediates and partial steps for their synthesis are described. The substituted pyrrolidine compounds are especially of the formula (I), wherein the substituents are as described in the specificacion.